Medica Ceftriaxone 1g (Ceftriaxone Sodium Hydrate)

Adult dosage

For ceftriaxone, administer 1-2 g (activity) once daily by intravenous or intramuscular injection. In cases of severe disease or infections caused by moderately susceptible pathogens, the dose may be increased up to 4 g (activity) once daily. For gonorrhea treatment, a single intramuscular injection of 250 mg (activity) is recommended. For prevention of infections before and after surgery, a single dose of 1-2 g (activity) is preferable 30-90 minutes prior to surgery.

Children's dosage

Neonates (within 14 days of birth) are administered 20-50 mg (activity) per kg body weight once daily, not exceeding 50 mg (activity) per kg. Administered regardless of whether the infant is premature or full-term.

This drug may cause precipitation when used in combination with calcium-containing solutions and should not be mixed or administered simultaneously with calcium-containing solutions. In particular, it should not be given to neonates under 28 days of age with calcium-containing solutions as it may lead to fatal side effects. Patients with allergies to this medication or those with hypersensitivity to cephalosporins or penicillins should not use it. Premature infants or neonates with jaundice or problems with bilirubin binding are also at risk if this drug is used and should not be administered. Patients with impaired kidney function or a history of allergies should use this drug cautiously, as dose adjustment and regular monitoring may be necessary. This medication may cause side effects like diarrhea, rash, liver function abnormalities, and decreased blood cell counts, so report any unusual symptoms to healthcare providers immediately. Regular checks of liver and kidney functions, and blood tests are important while using this drug. In case of overdose, since there is no specific antidote, symptomatic treatment should be provided, and patients should avoid driving or operating machinery if symptoms such as dizziness occur. Women who are pregnant or nursing should use this medication with caution and consult their physician regarding the potential effects on the fetus or infant. It is considered safer not to use this medication in children, especially neonates and premature infants, due to the risk of bilirubin encephalopathy. Older adults should be monitored closely for side effects due to declining physical function. This medication may interact with other drugs, so inform healthcare providers of any concomitant medications, particularly those that may increase renal toxicity. Injection sites may cause pain or inflammation, so care should be taken with the method and speed of injection, and prepared solutions should be used as soon as possible.

Serious side effects

Hives, severe swelling (edema), difficulty breathing, chest tightness, cold sweat, pallor, severe allergic reaction, severe skin reaction, jaundice (yellowing of skin or eyes), extreme fatigue, liver abnormalities (jaundice), sudden and severe headache, lightning headache, seizure, confusion, visual disturbances, paralysis, severe neurological symptoms, markedly reduced urine output, generalized severe swelling and increased blood pressure

Mild side effects

• Eosinophilia
• leukopenia
• thrombocytopenia
• diarrhea
• rash
• increased liver enzymes
• headache
• dizziness
• bronchospasm
• loose stools

This drug should be stored in a sealed container to prevent air or moisture ingress, and it is important to maintain storage temperatures between 1 to 30 degrees Celsius. Proper storage helps maintain the drug’s effectiveness and prevents degradation.

Appearance

A colorless, transparent vial containing white to pale yellow powder

Package unit

1g * 10 vials